A 6 month Multi-center, Open-label Safety Study of VIMOVO in Adolescents
-
Sponsor: AstraZeneca
Location(s): United States
Description
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, with Juvenile Idiopathic Arthritis (JIA)